Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radiolabeled TRV130 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Radiolabeled TRV130 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Radiolabeled TRV130 | DRUG | A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes |
Key Inclusion Criteria: * Males, between 18 and 64 years of age, inclusive * With body weight ≥ 50 kg and body mass index (BMI) between 18 and 32 kg/m2, inclusive * In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs * Negative test fo...
Radiolabeled TRV130 is an investigational small molecule being developed by Trevena, Inc. It is a carbon-14 labeled version of TRV130, used to study the metabolism and excretion of the drug in healthy male subjects. It is currently in Phase 1 clinical development.
Radiolabeled TRV130 is used to investigate the metabolism and excretion of TRV130 in healthy male subjects. It is a radiolabeled form of the drug that allows researchers to track how the compound is processed and eliminated from the body. It is not intended for therapeutic use.
Radiolabeled TRV130 is developed by Trevena, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol TRVN. The company is conducting clinical research on this compound to understand its pharmacokinetic properties.
Radiolabeled TRV130 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study in healthy volunteers. The drug is investigational and has not been approved for any therapeutic use.
Radiolabeled TRV130 has been studied in one completed clinical trial, NCT02169934, titled "A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects." This Phase 1 trial enrolled 6 healthy male participants in the United States.